Cell – Page 8 – Talk Bio

ArriVent Expands ADC Portfolio with $615 Million Alphamab Acquisition

11 months ago talkbio0Tagged Acquisition (action), Alphamab, ArriVent, Biotechnology, financing characteristics, portfolio, therapeutic autologous dendritic cells

ArriVent, ADC portfolio, Alphamab, acquisition, biotech, biotechnology, financing

Bionova Scientific Expands into Plasmid DNA Services for Cell and Gene Therapy Developers

11 months ago talkbio0Tagged Asahi Kasei, Biological Factors, Bionova, CDMO, Cells, DNA, Facility (object), gene therapy, Plasmids, Science, Texas

Bionova Scientific, Plasmid DNA, Cell and Gene Therapy, CDMO, Asahi Kasei Group, Biopharmaceuticals, Biologics, Texas Facility

Biotech Roundup: Compugen, Nxera Milestone Payments; Insmed Seeks $650M Offering

11 months ago talkbio0Tagged AstraZeneca, Bio, BMS, Breyanzi, Burning Mouth Syndrome, Celcuity, Compugen, K-ras Oncogene, luteolin-7-O-diglucuronide 4'-O-glucuronosyltransferase activity, milestone payments, Nordisk, Novartis, Nxera, United States Food and Drug Administration

Compugen, Nxera, milestone payments, Insmed, $650M offering, biotech, pharmaceuticals, Celcuity, Weave Bio, AstraZeneca, Novo Nordisk Foundation, FDA, LDT rule, BMS, Breyanzi, KRAS drug, Novartis

BioNTech Expands ADC Alliance with MediLink, Investing $1.8 Billion

11 months ago talkbio0Tagged ADC, alliance, BioNTech, gene therapy, MediLink, Molecular Biology, oligonucleotide therapy, therapeutic autologous dendritic cells

BioNTech, MediLink, ADC alliance, $1.8 billion, oligonucleotide therapy, gene therapy, molecular biology

Revolutionizing CAR-Ts: The Future of Automation and Decentralization in Cell and Gene Therapy Manufacturing

11 months ago11 months ago talkbio0Tagged Advanced therapies, Automation, CAR-Ts, Cells, Decentralization, Digital X-ray, gene therapy, Manufacture, Patient-Centered Care, Precision Medicine, Preventive monitoring, quality management systems, real-time, Regulatory Compliance, Supply chain logistics

Automation, Decentralization, CAR-Ts, Cell and gene therapy manufacturing, Advanced therapies, Personalized medicine, Regulatory compliance, Quality management systems, Supply chain logistics, Digital solutions, Real-time monitoring, Patient-centered care

AstraZeneca and Daiichi Sankyo’s TROP2 ADC Demonstrates Clinically Meaningful Survival Improvement in Phase 3 Lung Cancer Subgroup

11 months ago talkbio0Tagged AstraZeneca, Continuance of life, Daiichi, Datopotamab, Deruxtecan, Improvement, Malignant neoplasm of lung, Nonsquamous Non-Small Cell Lung Cancer, Phase 3 trial, Sankyo, TACSTD2 gene, therapeutic autologous dendritic cells

AstraZeneca, Daiichi Sankyo, TROP2 ADC, Datopotamab Deruxtecan, Lung Cancer, Phase 3 Trial, Survival Improvement, Nonsquamous Non-Small Cell Lung Cancer

FDA Greenlights Amgen’s Innovative T Cell Therapy for Aggressive Lung Cancer

11 months ago talkbio0Tagged Aggressive behavior, AMELX gene, amgen, bi-specific, Cancer Therapeutic Procedure, Clinical Trials, Immunotherapy, Malignant neoplasm of lung, Small cell carcinoma of lung, T-Lymphocyte, United States Food and Drug Administration

FDA, Amgen, T cell engager, lung cancer, aggressive, AMG 757, bi-specific T cell engager, small cell lung cancer, immunotherapy, cancer treatment, clinical trials.

Bristol Myers’ Breyanzi Expands Indications to Include Follicular Lymphoma

11 months ago talkbio0Tagged Approved, Breyanzi, Cancer Therapeutic Procedure, CAR-T, Immunotherapy, Lymphoma, Follicular, Myers, United States Food and Drug Administration

Bristol Myers, Breyanzi, CAR-T therapy, follicular lymphoma, FDA approval, cancer treatment, immunotherapy.

Bristol Myers’ Breyanzi Approved by FDA for Follicular Lymphoma, Joining Gilead and Novartis in CAR-T Treatment

11 months ago talkbio0Tagged Breyanzi, Cancer Therapeutic Procedure, CAR-T, Gilead, Immunotherapy, Lymphoma, Follicular, Myers, Novartis, United States Food and Drug Administration

Bristol Myers, Breyanzi, FDA, follicular lymphoma, CAR-T, Gilead, Novartis, cancer treatment, immunotherapy

ADC Therapeutics Showcases Promising Zynlonta Data in Marginal Zone Lymphoma and Secures $105M in Funding

12 months ago talkbio0Tagged Antibody-Drug Conjugates, Biotechnology, Cancer Therapeutic Procedure, Clinical Trials, Health care facility, Mucosa-Associated Lymphoid Tissue Lymphoma, Sales - occupational activity, therapeutic autologous dendritic cells, Zynlonta

ADC Therapeutics, Zynlonta, marginal zone lymphoma, share sale, funding, cancer treatment, antibody-drug conjugate, clinical trials, biotechnology, healthcare.